U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT07536269) titled 'Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old' on April 10.
Brief Summary: The main objective of this study is to assess the safety and tolerability of crinecerfont in pediatric participants 3 months to <4 years of age with CAH.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Congenital Adrenal Hyperplasia
Intervention:
DRUG: Crinecerfont
Oral solution
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Neurocrine Biosciences
Published by HT Digital Content Services with permission ...